Oura has agreed to acquire AI-powered primary-care startup Counsel Health for $625 million, extending the smart-ring company’s ambitions from tracking health signals to helping users act on them. Counsel combines a chat-based medical experience with access to licensed physicians, and its service was integrated into the Oura app in June. The acquisition expands an existing partnership and gives Oura a direct route into healthcare services that can sit alongside its wearable data. The announcement follows Oura’s decision to postpone a planned public provideing of up to $2.2 billion indefinitely, citing uncertainty in the IPO market. The deal signals that the company is pursuing growth through a broader health platform rather than relying only on hardware sales.
From physiological tracking to medical support
Counsel Health’s service combines software-based interaction with access to clinicians. Users can ask questions through an AI-supported chat interface and connect with a physician when the situation requires human medical input. The integration inside Oura’s app allows a member to move from viewing information about sleep, activity or other physiological signals toward a conversation about what that information might mean. The distinction between a wellness indicator and a medical conclusion is important. Wearables can detect patterns and changes, but they do not independently establish a diagnosis. A healthcare service must be designed to recognise when a question requires clinical judgement, examination or testing beyond the information collected by a ring.
Oura’s leadership has described the combination as a way to help members understand their physiology and take action across a wider range of needs. The companies plan to expand their work across preventive care, acute care, specialty services and chronic-care support. That ambition could create a more continuous relationship with users: a device collects information over time, an app presents trends, and a care service helps people decide what to do next. It may also make the Oura subscription more valuable by connecting measurements to services. But the value will depend on the quality of medical support, the availability of clinicians and the ability to keep advice appropriately grounded in a user’s actual health context.
The smart-ring market is becoming more competitive, with companies such as RingConn and Ultrahuman challenging Oura’s position. Hardware differentiation can become difficult when rival devices provide similar sleep, activity and recovery metrics. Adding healthcare services could create a broader ecosystem that is harder to reproduce than a wearable device alone. It may also provide a new source of revenue and strengthen customer retention. However, healthcare is operationally different from consumer electronics. A service that promises access to physicians must manage clinician capacity, patient expectations, clinical records, follow-up and regulatory requirements. Scaling those responsibilities across a large consumer membership base is more complicated than adding a software feature to a mobile app.
Clinical oversight and data governance will shape the integration
Counsel previously raised a $25 million Series A round led by Andreessen Horowitz and GV, and PitchBook estimated its total funding at $36 million. The $625 million acquisition price is So a substantial transaction relative to the startup’s disclosed funding history. Oura has not detailed every element of the deal structure in the information reported by TechCrunch. The acquisition should be assessed as a strategic purchase of a healthcare service and team, not as evidence that AI can replace doctors. Counsel’s combination of AI and licensed physicians suggests that human care remains part of the service model. The company will need to show that the technology improves access and coordination without creating unsafe shortcuts.
Several questions will determine whether the acquisition provides on its promise. Oura will need to explain how wearable data is shared with Counsel, what consent users provide and whether sensitive health information can be separated from other app activity. It will also need to clarify how medical conversations are stored, how clinicians review AI-generated suggestions and how urgent cases are escalated. Users should be able to understand when they are interacting with software and when they are receiving advice from a licensed professional. The acquisition gives Oura a larger role in digital health, but the quality of clinical governance and privacy controls will matter more than the novelty of combining an AI assistant with a wearable.